Bio-Techne Corporation (TECH)
USD 52.69
(-3.96%)
USD 52.69
(-3.96%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 2.81 Billion USD | 2.47% |
| 2023 | 2.63 Billion USD | 14.99% |
| 2022 | 2.29 Billion USD | 1.41% |
| 2021 | 2.26 Billion USD | 11.61% |
| 2020 | 2.02 Billion USD | 7.6% |
| 2019 | 1.88 Billion USD | 18.28% |
| 2018 | 1.59 Billion USD | 2.35% |
| 2017 | 1.55 Billion USD | 37.82% |
| 2016 | 1.12 Billion USD | 6.22% |
| 2015 | 1.06 Billion USD | 23.29% |
| 2014 | 862.49 Million USD | 10.85% |
| 2013 | 778.09 Million USD | 8.17% |
| 2012 | 719.32 Million USD | 16.46% |
| 2011 | 617.67 Million USD | 19.05% |
| 2010 | 518.81 Million USD | 9.92% |
| 2009 | 472 Million USD | -6.97% |
| 2008 | 507.36 Million USD | 11.55% |
| 2007 | 454.84 Million USD | 22.76% |
| 2006 | 370.51 Million USD | 25.49% |
| 2005 | 295.26 Million USD | -9.28% |
| 2004 | 325.46 Million USD | 23.62% |
| 2003 | 263.27 Million USD | 10.51% |
| 2002 | 238.24 Million USD | 10.54% |
| 2001 | 215.52 Million USD | 19.46% |
| 2000 | 180.4 Million USD | 45.73% |
| 1999 | 123.8 Million USD | 69.82% |
| 1998 | 72.9 Million USD | 35.25% |
| 1997 | 53.9 Million USD | 21.4% |
| 1996 | 44.4 Million USD | 30.21% |
| 1995 | 34.1 Million USD | 27.24% |
| 1994 | 26.8 Million USD | 31.37% |
| 1993 | 20.4 Million USD | 29.94% |
| 1992 | 15.7 Million USD | 63.54% |
| 1991 | 9.6 Million USD | 20.0% |
| 1990 | 8 Million USD | 31.15% |
| 1989 | 6.1 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 2.81 Billion USD | 3.38% |
| 2024 FY | 2.81 Billion USD | 6.61% |
| 2024 Q2 | 2.73 Billion USD | -0.89% |
| 2024 Q1 | 2.75 Billion USD | 4.42% |
| 2024 Q3 | 2.72 Billion USD | -0.35% |
| 2023 Q4 | 2.63 Billion USD | 1.5% |
| 2023 FY | 2.63 Billion USD | 14.99% |
| 2023 Q2 | 2.36 Billion USD | 0.54% |
| 2023 Q3 | 2.59 Billion USD | 10.0% |
| 2023 Q1 | 2.35 Billion USD | 2.44% |
| 2022 Q2 | 2.3 Billion USD | 1.53% |
| 2022 Q1 | 2.27 Billion USD | 0.32% |
| 2022 FY | 2.29 Billion USD | 1.41% |
| 2022 Q4 | 2.29 Billion USD | -0.22% |
| 2022 Q3 | 2.29 Billion USD | -0.21% |
| 2021 Q4 | 2.26 Billion USD | 8.55% |
| 2021 Q1 | 2.05 Billion USD | 1.26% |
| 2021 FY | 2.26 Billion USD | 11.61% |
| 2021 Q2 | 2.06 Billion USD | 0.72% |
| 2021 Q3 | 2.08 Billion USD | 0.81% |
| 2020 Q4 | 2.02 Billion USD | 1.43% |
| 2020 FY | 2.02 Billion USD | 7.6% |
| 2020 Q2 | 1.99 Billion USD | 3.81% |
| 2020 Q1 | 1.92 Billion USD | 2.16% |
| 2020 Q3 | 1.99 Billion USD | 0.03% |
| 2019 FY | 1.88 Billion USD | 18.28% |
| 2019 Q2 | 1.84 Billion USD | -1.46% |
| 2019 Q3 | 1.87 Billion USD | 1.51% |
| 2019 Q1 | 1.87 Billion USD | 17.51% |
| 2019 Q4 | 1.88 Billion USD | 0.63% |
| 2018 Q2 | 1.55 Billion USD | 1.84% |
| 2018 Q4 | 1.59 Billion USD | -1.54% |
| 2018 Q1 | 1.52 Billion USD | -1.88% |
| 2018 FY | 1.59 Billion USD | 2.35% |
| 2018 Q3 | 1.61 Billion USD | 4.03% |
| 2017 Q1 | 1.51 Billion USD | 34.35% |
| 2017 Q2 | 1.52 Billion USD | 0.17% |
| 2017 Q3 | 1.53 Billion USD | 0.88% |
| 2017 Q4 | 1.55 Billion USD | 1.51% |
| 2017 FY | 1.55 Billion USD | 37.82% |
| 2016 Q4 | 1.12 Billion USD | -1.44% |
| 2016 Q3 | 1.14 Billion USD | 1.11% |
| 2016 Q2 | 1.13 Billion USD | 0.45% |
| 2016 Q1 | 1.12 Billion USD | 6.11% |
| 2016 FY | 1.12 Billion USD | 6.22% |
| 2015 Q2 | 1.11 Billion USD | 9.89% |
| 2015 FY | 1.06 Billion USD | 23.29% |
| 2015 Q1 | 1.01 Billion USD | 18.06% |
| 2015 Q3 | 1.1 Billion USD | -1.31% |
| 2015 Q4 | 1.06 Billion USD | -3.71% |
| 2014 Q4 | 862.49 Million USD | 3.84% |
| 2014 FY | 862.49 Million USD | 10.85% |
| 2014 Q1 | 779.29 Million USD | 0.15% |
| 2014 Q2 | 802.16 Million USD | 2.94% |
| 2014 Q3 | 830.56 Million USD | 3.54% |
| 2013 Q3 | 760.29 Million USD | 4.93% |
| 2013 Q2 | 724.57 Million USD | 1.68% |
| 2013 Q1 | 712.62 Million USD | -0.93% |
| 2013 FY | 778.09 Million USD | 8.17% |
| 2013 Q4 | 778.09 Million USD | 2.34% |
| 2012 Q4 | 719.32 Million USD | 5.16% |
| 2012 Q3 | 684.03 Million USD | 9.58% |
| 2012 Q2 | 624.24 Million USD | -0.67% |
| 2012 FY | 719.32 Million USD | 16.46% |
| 2012 Q1 | 628.43 Million USD | 1.74% |
| 2011 Q4 | 617.67 Million USD | 5.98% |
| 2011 Q1 | 539.62 Million USD | 4.01% |
| 2011 Q2 | 555.6 Million USD | 2.96% |
| 2011 Q3 | 582.81 Million USD | 4.9% |
| 2011 FY | 617.67 Million USD | 19.05% |
| 2010 Q4 | 518.81 Million USD | -0.59% |
| 2010 FY | 518.81 Million USD | 9.92% |
| 2010 Q3 | 521.89 Million USD | 3.91% |
| 2010 Q2 | 502.23 Million USD | 3.12% |
| 2010 Q1 | 487.04 Million USD | 3.19% |
| 2009 Q1 | 507.66 Million USD | 0.06% |
| 2009 Q4 | 472 Million USD | 6.84% |
| 2009 FY | 472 Million USD | -6.97% |
| 2009 Q3 | 441.8 Million USD | 1.91% |
| 2009 Q2 | 433.53 Million USD | -14.6% |
| 2008 Q2 | 488.21 Million USD | 1.49% |
| 2008 Q3 | 488.11 Million USD | -0.02% |
| 2008 FY | 507.36 Million USD | 11.55% |
| 2008 Q1 | 481.05 Million USD | 5.76% |
| 2008 Q4 | 507.36 Million USD | 3.95% |
| 2007 Q1 | 389.2 Million USD | 5.05% |
| 2007 Q2 | 397.64 Million USD | 2.17% |
| 2007 FY | 454.84 Million USD | 22.76% |
| 2007 Q3 | 427.17 Million USD | 7.43% |
| 2007 Q4 | 454.84 Million USD | 6.48% |
| 2006 Q2 | 310.11 Million USD | -2.63% |
| 2006 Q3 | 342.12 Million USD | 10.32% |
| 2006 Q4 | 370.51 Million USD | 8.3% |
| 2006 FY | 370.51 Million USD | 25.49% |
| 2006 Q1 | 318.48 Million USD | 7.86% |
| 2005 Q1 | 342.62 Million USD | 5.27% |
| 2005 FY | 295.26 Million USD | -9.28% |
| 2005 Q3 | 277.98 Million USD | -22.67% |
| 2005 Q2 | 359.48 Million USD | 4.92% |
| 2005 Q4 | 295.26 Million USD | 6.21% |
| 2004 FY | 325.46 Million USD | 23.62% |
| 2004 Q3 | 312.6 Million USD | 6.41% |
| 2004 Q2 | 293.78 Million USD | 5.94% |
| 2004 Q1 | 277.3 Million USD | 5.33% |
| 2004 Q4 | 325.46 Million USD | 4.11% |
| 2003 Q1 | 249.21 Million USD | 4.6% |
| 2003 FY | 263.27 Million USD | 10.51% |
| 2003 Q4 | 263.27 Million USD | 4.39% |
| 2003 Q3 | 252.2 Million USD | -0.45% |
| 2003 Q2 | 253.33 Million USD | 1.65% |
| 2002 Q2 | 228.03 Million USD | 2.02% |
| 2002 FY | 238.24 Million USD | 10.54% |
| 2002 Q4 | 238.24 Million USD | -0.19% |
| 2002 Q3 | 238.71 Million USD | 4.68% |
| 2002 Q1 | 223.53 Million USD | 3.72% |
| 2001 Q4 | 215.52 Million USD | 6.82% |
| 2001 Q3 | 201.76 Million USD | 3.43% |
| 2001 Q1 | 186.23 Million USD | 3.23% |
| 2001 Q2 | 195.07 Million USD | 4.75% |
| 2001 FY | 215.52 Million USD | 19.46% |
| 2000 Q3 | 165.59 Million USD | 8.09% |
| 2000 Q1 | 150 Million USD | 21.16% |
| 2000 FY | 180.4 Million USD | 45.73% |
| 2000 Q4 | 180.4 Million USD | 8.95% |
| 2000 Q2 | 153.2 Million USD | 2.13% |
| 1999 Q3 | 120.5 Million USD | 5.15% |
| 1999 Q4 | 123.8 Million USD | 2.74% |
| 1999 Q2 | 114.6 Million USD | 0.61% |
| 1999 Q1 | 113.9 Million USD | 56.24% |
| 1999 FY | 123.8 Million USD | 69.82% |
| 1998 Q4 | 72.9 Million USD | 8.97% |
| 1998 Q3 | 66.9 Million USD | 8.43% |
| 1998 Q2 | 61.7 Million USD | 4.75% |
| 1998 FY | 72.9 Million USD | 35.25% |
| 1998 Q1 | 58.9 Million USD | 9.28% |
| 1997 Q2 | 47.6 Million USD | 5.54% |
| 1997 FY | 53.9 Million USD | 21.4% |
| 1997 Q4 | 53.9 Million USD | 10.91% |
| 1997 Q1 | 45.1 Million USD | 1.58% |
| 1997 Q3 | 48.6 Million USD | 2.1% |
| 1996 Q4 | 44.4 Million USD | 10.17% |
| 1996 FY | 44.4 Million USD | 30.21% |
| 1996 Q3 | 40.3 Million USD | 8.92% |
| 1996 Q2 | 37 Million USD | 1.93% |
| 1996 Q1 | 36.3 Million USD | 6.45% |
| 1995 Q1 | 28.4 Million USD | 5.97% |
| 1995 FY | 34.1 Million USD | 27.24% |
| 1995 Q4 | 34.1 Million USD | 7.23% |
| 1995 Q3 | 31.8 Million USD | 9.28% |
| 1995 Q2 | 29.1 Million USD | 2.46% |
| 1994 Q4 | 26.8 Million USD | 5.51% |
| 1994 Q1 | 22.7 Million USD | 11.27% |
| 1994 Q2 | 23 Million USD | 1.32% |
| 1994 Q3 | 25.4 Million USD | 10.43% |
| 1994 FY | 26.8 Million USD | 31.37% |
| 1993 FY | 20.4 Million USD | 29.94% |
| 1993 Q2 | 17.3 Million USD | 4.22% |
| 1993 Q3 | 19 Million USD | 9.83% |
| 1993 Q4 | 20.4 Million USD | 7.37% |
| 1993 Q1 | 16.6 Million USD | 5.73% |
| 1992 Q4 | 15.7 Million USD | 9.03% |
| 1992 FY | 15.7 Million USD | 63.54% |
| 1992 Q1 | 14.5 Million USD | 51.04% |
| 1992 Q2 | 13.3 Million USD | -8.28% |
| 1992 Q3 | 14.4 Million USD | 8.27% |
| 1991 Q4 | 9.6 Million USD | 4.35% |
| 1991 Q3 | 9.2 Million USD | 3.37% |
| 1991 Q2 | 8.9 Million USD | 3.49% |
| 1991 Q1 | 8.6 Million USD | 7.5% |
| 1991 FY | 9.6 Million USD | 20.0% |
| 1990 FY | 8 Million USD | 31.15% |
| 1990 Q4 | 8 Million USD | 5.26% |
| 1990 Q3 | 7.6 Million USD | 2.7% |
| 1990 Q2 | 7.4 Million USD | 13.85% |
| 1990 Q1 | 6.5 Million USD | 0.0% |
| 1989 FY | 6.1 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | -89.047% |
| Alkermes plc | 2.13 Billion USD | -31.69% |
| Agenus Inc. | 313.91 Million USD | -796.169% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 26.546% |
| Aptorum Group Limited | 20.64 Million USD | -13529.736% |
| Ardelyx, Inc. | 297.57 Million USD | -845.359% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -267.472% |
| Bicycle Therapeutics plc | 595.34 Million USD | -372.532% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -3716.979% |
| ChromaDex Corporation | 54.96 Million USD | -5018.241% |
| Chimerix, Inc. | 212.77 Million USD | -1222.149% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -9850.307% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -537.958% |
| CRISPR Therapeutics AG | 2.22 Billion USD | -26.176% |
| Precision BioSciences, Inc. | 159.78 Million USD | -1660.654% |
| Dyadic International, Inc. | 8.21 Million USD | -34126.904% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -8763.233% |
| Fortress Biotech, Inc. | 167.52 Million USD | -1579.256% |
| Lantern Pharma Inc. | 43.64 Million USD | -6345.232% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -1643.673% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -19292.421% |
| Incyte Corporation | 6.78 Billion USD | 58.52% |
| IO Biotech, Inc. | 150.71 Million USD | -1766.526% |
| Jaguar Health, Inc. | 50.76 Million USD | -5441.812% |
| Novavax, Inc. | 1.85 Billion USD | -51.626% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -639.521% |
| Opthea Limited | 188.79 Million USD | -1390.106% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -237.692% |
| ContextLogic Inc. | 423 Million USD | -565.057% |
| MiMedx Group, Inc. | 239.04 Million USD | -1076.836% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -1519.326% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -54316.88% |
| NextCure, Inc. | 129.41 Million USD | -2073.724% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -5114.633% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -7559.316% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -8609.297% |
| Vaxcyte, Inc. | 1.4 Billion USD | -99.812% |
| PDS Biotechnology Corporation | 59.39 Million USD | -4636.801% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -339.186% |
| Pharming Group N.V. | 462.85 Million USD | -507.792% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -7172.983% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -347.565% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -14765.981% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -14765.981% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -1601.663% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -6111.915% |
| Acelyrin, Inc. | 742.69 Million USD | -278.784% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -42611.306% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -43835.499% |
| Summit Therapeutics Inc. | 202.94 Million USD | -1286.156% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -3682.491% |
| Senti Biosciences, Inc. | 119.48 Million USD | -2254.449% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -1132.007% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -1572.785% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -33945.625% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -58830.178% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -499.582% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -2175.068% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -923.168% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -494.956% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -27739.584% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -1211.474% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -248380.116% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -579.774% |
| Immix Biopharma, Inc. | 19.92 Million USD | -14018.782% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -660.27% |
| MEI Pharma, Inc. | 41.37 Million USD | -6699.251% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -8581.078% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -725.471% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -2299.821% |
| Fortress Biotech, Inc. | 167.52 Million USD | -1579.256% |
| Precigen, Inc. | 151.04 Million USD | -1762.509% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -8169.71% |
| AlloVir, Inc. | 190.79 Million USD | -1374.449% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -647.292% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -455.728% |
| ImmuCell Corporation | 43.8 Million USD | -6321.62% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -333.254% |
| Onconetix, Inc. | 88.82 Million USD | -3067.242% |
| PureTech Health plc | 693.97 Million USD | -305.375% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -2779.859% |
| Elevation Oncology, Inc. | 89.09 Million USD | -3057.659% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -45259.4% |
| Seer, Inc. | 436.26 Million USD | -544.829% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -3347.664% |
| Innoviva, Inc. | 1.24 Billion USD | -126.23% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -2024.397% |
| ESSA Pharma Inc. | 149.12 Million USD | -1786.501% |
| GlycoMimetics, Inc. | 45.31 Million USD | -6107.875% |
| GT Biopharma, Inc. | 14.1 Million USD | -19838.975% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -813.691% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -1063.904% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -496.132% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -5449.027% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -2854.659% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -445315.366% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -396.731% |
| Aptose Biosciences Inc. | 12.92 Million USD | -21669.63% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -12621.144% |
| Soligenix, Inc. | 9.79 Million USD | -28613.855% |
| Century Therapeutics, Inc. | 360.69 Million USD | -679.945% |
| Kura Oncology, Inc. | 448.93 Million USD | -526.636% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -933.695% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -16165.915% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -2436.432% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -1271.278% |
| Autolus Therapeutics plc | 375.38 Million USD | -649.423% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -1017.96% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -692.037% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -5625.78% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -325.51% |
| GRI Bio, Inc. | 2.95 Million USD | -95068.809% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -26426.45% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -1549.82% |
| IGM Biosciences, Inc. | 423.41 Million USD | -564.411% |
| INmune Bio, Inc. | 57 Million USD | -4835.334% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -1164.321% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -3251.38% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -10671.548% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -40770.41% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -3639.651% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -1810.382% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -1599.772% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -346.819% |
| Verastem, Inc. | 149.71 Million USD | -1778.993% |
| Abeona Therapeutics Inc. | 64 Million USD | -4295.472% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -449.286% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -1721.342% |
| Histogen Inc. | 19.07 Million USD | -14649.594% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -12320.169% |
| Surrozen, Inc. | 46.08 Million USD | -6005.013% |
| Organovo Holdings, Inc. | 6.34 Million USD | -44209.183% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -65192.135% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -1853.241% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -23736.553% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -3637.564% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -32921.569% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -675.05% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -15447.299% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -555.141% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -22206.156% |
| Apollomics, Inc. | 55.38 Million USD | -4979.152% |
| Amarin Corporation plc | 831.68 Million USD | -238.252% |
| Mesoblast Limited | 669.15 Million USD | -320.411% |
| Turnstone Biologics Corp. | 112.81 Million USD | -2393.631% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -388.605% |
| Synaptogenix, Inc. | 31.11 Million USD | -8941.654% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -22989.215% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -413.298% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -47806.42% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -38199.92% |
| Exelixis, Inc. | 2.94 Billion USD | 4.39% |
| Better Therapeutics, Inc. | 22.94 Million USD | -12161.648% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -671.712% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -256.673% |
| NLS Pharmaceutics AG | 1.84 Million USD | -152240.926% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -35159.043% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -19043.858% |
| Gritstone bio, Inc. | 177.76 Million USD | -1482.498% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -2849.455% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -15649.342% |
| Avid Bioservices, Inc. | 336.55 Million USD | -735.873% |
| Insmed Incorporated | 1.32 Billion USD | -111.544% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -29117.794% |
| MediWound Ltd. | 66.45 Million USD | -4132.971% |
| OmniAb, Inc. | 401.98 Million USD | -599.825% |
| Alector, Inc. | 621.82 Million USD | -352.407% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -684.492% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -52209.223% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -4862.235% |
| Zai Lab Limited | 1.03 Billion USD | -171.466% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -487.975% |
| Aura Biosciences, Inc. | 255.07 Million USD | -1002.887% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -275.077% |
| Immunic, Inc. | 54.29 Million USD | -5080.924% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -956.7% |
| Veracyte, Inc. | 1.13 Billion USD | -147.244% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -23694.653% |
| FibroGen, Inc. | 423.52 Million USD | -564.226% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -79979.419% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -59292.54% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -51713.268% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 75.309% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -31849.915% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -443.66% |
| TG Therapeutics, Inc. | 329.58 Million USD | -753.55% |
| Galecto, Inc. | 38.22 Million USD | -7259.17% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -9710.259% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 35.436% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -1095.048% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -11224.33% |
| XBiotech Inc. | 227.24 Million USD | -1137.966% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -2849.455% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -1872.784% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -883.922% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -2100.056% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -636.439% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | -88.676% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -671.071% |
| Vaxxinity, Inc. | 44.35 Million USD | -6242.728% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -444.179% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -15017.094% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -822.206% |
| NexImmune, Inc. | 8.59 Million USD | -32634.544% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -26154.224% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -16325.094% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 91.496% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -12599.984% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -717065.692% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -1523.035% |
| Ainos, Inc. | 31.84 Million USD | -8734.895% |
| Pluri Inc. | 39.52 Million USD | -7017.135% |
| Prothena Corporation plc | 696.38 Million USD | -303.972% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -895.411% |
| Celularity Inc. | 143.88 Million USD | -1855.111% |
| Rallybio Corporation | 115.62 Million USD | -2333.134% |
| Cue Biopharma, Inc. | 61.53 Million USD | -4472.062% |
| MeiraGTx Holdings plc | 458.16 Million USD | -514.008% |
| Omeros Corporation | 378.26 Million USD | -643.701% |
| Humacyte, Inc. | 128.22 Million USD | -2093.982% |
| Immunocore Holdings plc | 597 Million USD | -371.22% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -8899.616% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -4005.049% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -168.114% |
| CalciMedica, Inc. | 12.18 Million USD | -22987.32% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -1009.083% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -1546.026% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -804.461% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -397.646% |
| Pulmatrix, Inc. | 33.95 Million USD | -8184.322% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -10263.184% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -1897.182% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -116.237% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -2060.85% |
| Cytokinetics, Incorporated | 824.31 Million USD | -241.276% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -13218.137% |
| Nutriband Inc. | 7.51 Million USD | -37323.605% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -3463.075% |
| Vor Biopharma Inc. | 209.82 Million USD | -1240.712% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 61.05% |
| Evogene Ltd. | 51.1 Million USD | -5405.156% |
| ProKidney Corp. | 420.55 Million USD | -568.928% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -5030.469% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -29449.452% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -414.878% |
| CorMedix Inc. | 82.05 Million USD | -3328.213% |
| BioLineRx Ltd. | 63.92 Million USD | -4300.767% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -598.813% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -9875.851% |
| Atai Life Sciences N.V. | 293.47 Million USD | -858.569% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -1624.514% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -2107.843% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -400.544% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -2808.622% |
| MediciNova, Inc. | 66.26 Million USD | -4145.044% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -3098.697% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -62942.579% |
| GeoVax Labs, Inc. | 9.28 Million USD | -30204.036% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -378.242% |
| Biomea Fusion, Inc. | 199.92 Million USD | -1307.109% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | -47.815% |
| Mereo BioPharma Group plc | 66.49 Million USD | -4130.425% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -479.924% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -359.012% |
| Absci Corporation | 234.48 Million USD | -1099.757% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -38357.826% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -727.674% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -1604.117% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -434.5% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -913.058% |
| Allakos Inc. | 243.61 Million USD | -1054.792% |
| Imunon, Inc. | 21.91 Million USD | -12735.027% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -991.679% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -352.633% |
| BioAtla, Inc. | 119.65 Million USD | -2251.025% |
| NLS Pharmaceutics AG | 1.84 Million USD | -152240.926% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -87266.149% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -337.621% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -2832.392% |
| XOMA Corporation | 234.3 Million USD | -1100.673% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -1171.585% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -2135.458% |
| aTyr Pharma, Inc. | 122.06 Million USD | -2204.628% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -1727.898% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -384.806% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -473.624% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -2446.588% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -18459.651% |
| Akari Therapeutics, Plc | 4.35 Million USD | -64496.785% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -16411.915% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -62.305% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -91119.286% |
| UroGen Pharma Ltd. | 178.31 Million USD | -1477.687% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -497.615% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -506128.912% |
| Orgenesis Inc. | 14.55 Million USD | -19231.982% |
| Entera Bio Ltd. | 11.76 Million USD | -23811.517% |
| GH Research PLC | 226.3 Million USD | -1143.124% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -5043.508% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -2518.48% |
| Xencor, Inc. | 952.69 Million USD | -195.289% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -36041.736% |
| Replimune Group, Inc. | 487.72 Million USD | -476.802% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -34755.148% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -333.84% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -91119.286% |
| Portage Biotech Inc. | 7.77 Million USD | -36063.903% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -62942.579% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -915.794% |
| OncoCyte Corporation | 74.89 Million USD | -3656.329% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -138259.413% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -48515.233% |
| Purple Biotech Ltd. | 44.3 Million USD | -6250.029% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -8143.539% |
| scPharmaceuticals Inc. | 94.47 Million USD | -2877.582% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -15489.895% |
| HilleVax, Inc. | 344.43 Million USD | -716.757% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -88476.511% |
| Tharimmune, Inc. | 10.94 Million USD | -25599.699% |
| Genprex, Inc. | 10.67 Million USD | -26263.954% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -466.953% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -2822.734% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -115860.016% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -67436.427% |
| OKYO Pharma Limited | 1.54 Million USD | -182424.863% |
| Savara Inc. | 177.56 Million USD | -1484.325% |
| Curis, Inc. | 77.28 Million USD | -3540.162% |
| Daré Bioscience, Inc. | 21.28 Million USD | -13118.502% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -4299.128% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -34690.873% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -14422.689% |
| BeiGene, Ltd. | 5.8 Billion USD | 51.541% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -23017.676% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | -34.693% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -685.915% |
| Erasca, Inc. | 395.29 Million USD | -611.665% |
| bluebird bio, Inc. | 619.16 Million USD | -354.355% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -64969.394% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 58.881% |
| DBV Technologies S.A. | 182.98 Million USD | -1437.38% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -64969.394% |
| Moderna, Inc. | 18.42 Billion USD | 84.732% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -15342.663% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -24180.943% |
| Molecular Templates, Inc. | 35.38 Million USD | -7850.683% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -1934.636% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -256.591% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -826.138% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -2606.396% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -504.172% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -797.53% |
| MacroGenics, Inc. | 306.82 Million USD | -816.886% |
| RenovoRx, Inc. | 1.46 Million USD | -191795.634% |
| Adicet Bio, Inc. | 207.29 Million USD | -1257.095% |
| Prime Medicine, Inc. | 193.85 Million USD | -1351.213% |
| Aditxt, Inc. | 44.57 Million USD | -6210.668% |
| Adagene Inc. | 115.72 Million USD | -2330.846% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -63058.299% |
| Quantum-Si incorporated | 298.25 Million USD | -843.232% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | -89.128% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -36391.7% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -700.838% |
| SciSparc Ltd. | 11.18 Million USD | -25058.201% |
| Vericel Corporation | 353.65 Million USD | -695.457% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -22935.127% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -4844.042% |
| Generation Bio Co. | 374.75 Million USD | -650.668% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -1004.659% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -1674.133% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -724.1% |
| Invivyd, Inc. | 229.18 Million USD | -1127.497% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -233.324% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -23017.104% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -1442.404% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -13673.942% |
| 2seventy bio, Inc. | 565.42 Million USD | -397.535% |
| ADMA Biologics, Inc. | 329.18 Million USD | -754.6% |
| Clene Inc. | 52.34 Million USD | -5274.735% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -4689.686% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -2065.758% |
| GeoVax Labs, Inc. | 9.28 Million USD | -30204.036% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -330.349% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -2615.142% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -2057.586% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -2783.784% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -3862.407% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -1059.825% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | -43.524% |
| Evaxion Biotech A/S | 12.88 Million USD | -21726.931% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -1016.08% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -273.752% |
| Trevena, Inc. | 40.6 Million USD | -6828.186% |
| Surrozen, Inc. | 46.08 Million USD | -6005.013% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -1145.562% |
| Cingulate Inc. | 3.49 Million USD | -80474.01% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -16817.373% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -4182.524% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -23975.993% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -947.677% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -275.615% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -2134.606% |
| Clearmind Medicine Inc. | 4.32 Million USD | -64954.046% |
| Kronos Bio, Inc. | 213.27 Million USD | -1219.019% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -1660.621% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -32762.027% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -663.437% |
| Statera Biopharma, Inc. | 21.16 Million USD | -13188.766% |
| ImmunityBio, Inc. | 504.45 Million USD | -457.672% |
| Korro Bio, Inc. | 221.66 Million USD | -1169.129% |
| Kineta, Inc. | 10.28 Million USD | -27263.0% |
| BioVie Inc. | 25.2 Million USD | -11059.757% |
| Codexis, Inc. | 136.56 Million USD | -1960.024% |
| Celularity Inc. | 143.88 Million USD | -1855.111% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -342.776% |
| Celcuity Inc. | 191.21 Million USD | -1371.184% |
| Virax Biolabs Group Limited | 5.48 Million USD | -51198.43% |
| Cibus, Inc. | 544.41 Million USD | -416.74% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -2134.57% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -13593.487% |
| IN8bio, Inc. | 33.7 Million USD | -8245.516% |
| Kodiak Sciences Inc. | 479.37 Million USD | -486.849% |
| Annexon, Inc. | 297.67 Million USD | -845.057% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -1526.027% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -1946.418% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -13300.61% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 5.916% |
| Eyenovia, Inc. | 28.77 Million USD | -9675.022% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -1120.325% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -38842.276% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -4517.388% |
| Arcellx, Inc. | 825.13 Million USD | -240.938% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -3345.974% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -508.553% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -9048.585% |
| Moolec Science SA | 24.05 Million USD | -11596.629% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -807.115% |
| Geron Corporation | 394.07 Million USD | -613.87% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -2665.893% |
| Royalty Pharma plc | 16.38 Billion USD | 82.827% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -372.83% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -40118.219% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -23290.007% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -1144.444% |
| Humacyte, Inc. | 128.22 Million USD | -2093.982% |
| Structure Therapeutics Inc. | 482.01 Million USD | -483.629% |
| 89bio, Inc. | 596.26 Million USD | -371.799% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -1015.672% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -151964.324% |
| Genelux Corporation | 27.89 Million USD | -9985.649% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -3046.639% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -1126.17% |
| Notable Labs, Ltd. | 19.54 Million USD | -14296.346% |
| Liquidia Corporation | 120.43 Million USD | -2235.935% |
| Mustang Bio, Inc. | 17.74 Million USD | -15756.104% |
| Immunovant, Inc. | 666.71 Million USD | -321.95% |
| Quantum-Si incorporated | 298.25 Million USD | -843.232% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -1848.179% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -5094.221% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -1502.537% |
| Acasti Pharma Inc. | 73.3 Million USD | -3737.913% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -61697.371% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -10671.548% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | -191.583% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -54104.903% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -12248.843% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -5351.602% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -1456.907% |
| PepGen Inc. | 143.05 Million USD | -1866.551% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -7261.096% |
| United Therapeutics Corporation | 7.16 Billion USD | 60.748% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -14563.487% |
| Solid Biosciences Inc. | 164.93 Million USD | -1605.594% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -47806.42% |
| Immuneering Corporation | 102.58 Million USD | -2642.314% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -65192.135% |
| Silo Pharma, Inc. | 7.74 Million USD | -36217.309% |
| Belite Bio, Inc | 94.64 Million USD | -2872.454% |
| XOMA Corporation | 234.3 Million USD | -1100.673% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -1106.404% |
| Bionomics Limited | 27.64 Million USD | -10074.619% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -600.838% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -2519.65% |
| uniQure N.V. | 831.68 Million USD | -238.25% |
| Cassava Sciences, Inc. | 151.66 Million USD | -1754.895% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -63058.299% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -927.143% |
| Forte Biosciences, Inc. | 38.98 Million USD | -7117.009% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -68967.303% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -7538.104% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -38842.276% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -79979.419% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -23698.24% |
| Altimmune, Inc. | 210.64 Million USD | -1235.544% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -261.648% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -2519.65% |
| Compugen Ltd. | 121.33 Million USD | -2218.55% |
| Peak Bio, Inc. | 2.59 Million USD | -108249.012% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -1532.472% |
| Benitec Biopharma Inc. | 52.21 Million USD | -5288.221% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -722.909% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -7990.156% |
| Zura Bio Limited | 100.84 Million USD | -2689.673% |
| PolyPid Ltd. | 15.37 Million USD | -18200.742% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -2258.357% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -7990.156% |
| Instil Bio, Inc. | 325.63 Million USD | -763.922% |
| argenx SE | 4.54 Billion USD | 38.069% |
| Immunome, Inc. | 148.54 Million USD | -1793.894% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -1693.269% |
| Verona Pharma plc | 308.12 Million USD | -813.006% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -3135.076% |
| Shattuck Labs, Inc. | 159.56 Million USD | -1663.048% |
| CervoMed Inc. | 9.97 Million USD | -28109.417% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -1392.757% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -24603.109% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -1468.067% |
| Moolec Science SA | 24.05 Million USD | -11596.629% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -45886.092% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -1526.644% |
| AnaptysBio, Inc. | 452.38 Million USD | -521.852% |
| Design Therapeutics, Inc. | 289.64 Million USD | -871.261% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -3762.945% |
| NeurAxis, Inc. | 509.49 Thousand USD | -552049.371% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -51823.034% |
| Lumos Pharma, Inc. | 40.63 Million USD | -6822.56% |
| Achilles Therapeutics plc | 161.45 Million USD | -1642.388% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -3135.076% |
| 180 Life Sciences Corp. | 5.25 Million USD | -53388.028% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -3894.431% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -32762.027% |
| Nutriband Inc. | 7.51 Million USD | -37323.605% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -1004.572% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -1311.528% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -3591.269% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -4757.362% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -434.278% |
| Palisade Bio, Inc. | 14.05 Million USD | -19919.855% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -1237.735% |
| Beam Therapeutics Inc. | 1.45 Billion USD | -92.722% |
| Neurogene Inc. | 222.57 Million USD | -1163.94% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -335.06% |
| AEON Biopharma, Inc. | 6.84 Million USD | -40998.466% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -520.964% |
| Sesen Bio, Inc. | 189.17 Million USD | -1387.091% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -934.767% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -20416.458% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -260.503% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -953.653% |
| Athira Pharma, Inc. | 160.24 Million USD | -1655.556% |
| Vaccinex, Inc. | 3.63 Million USD | -77377.004% |
| HCW Biologics Inc. | 28.51 Million USD | -9766.113% |
| XOMA Corporation | 234.3 Million USD | -1100.673% |
| Nektar Therapeutics | 398.03 Million USD | -606.773% |
| Arvinas, Inc. | 1.3 Billion USD | -115.636% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -16411.915% |
| Merus N.V. | 458.49 Million USD | -513.572% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -1276.545% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -1461.114% |
| Rezolute, Inc. | 132.73 Million USD | -2019.371% |
| Clene Inc. | 52.34 Million USD | -5274.735% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -18750.261% |
| BeyondSpring Inc. | 24.8 Million USD | -11239.85% |
| Synlogic, Inc. | 75.55 Million USD | -3623.614% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -23615.984% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -29942.61% |
| Peak Bio, Inc. | 2.59 Million USD | -108249.012% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -1509.073% |
| Krystal Biotech, Inc. | 818.35 Million USD | -243.762% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -1070.027% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -287.605% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -78542.806% |
| MannKind Corporation | 475.19 Million USD | -492.004% |
| Ikena Oncology, Inc. | 192.09 Million USD | -1364.501% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -20934.769% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -2313.947% |
| Gossamer Bio, Inc. | 311.91 Million USD | -801.906% |
| CohBar, Inc. | 16.36 Million USD | -17089.584% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -7900.427% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -38357.826% |
| Legend Biotech Corporation | 1.84 Billion USD | -52.179% |
| Mural Oncology plc | 301.74 Million USD | -832.307% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -8912.302% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -49424.462% |
| Disc Medicine, Inc. | 367.99 Million USD | -664.462% |
| Champions Oncology, Inc. | 26.13 Million USD | -10665.307% |
| REGENXBIO Inc. | 573.97 Million USD | -390.128% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -103781.156% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -1722.179% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -23196.521% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -727.324% |
| Vaxart, Inc. | 91.83 Million USD | -2963.476% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -4596.173% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -1796.615% |
| Cellectis S.A. | 334.27 Million USD | -741.592% |
| Longeveron Inc. | 12.17 Million USD | -23000.591% |
| Repare Therapeutics Inc. | 253.9 Million USD | -1007.987% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 13.827% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -1300.663% |
| Revolution Medicines, Inc. | 2.08 Billion USD | -34.693% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -173019.385% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -912.992% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -1624.846% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -1927.612% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -10922.608% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 87.624% |
| Denali Therapeutics Inc. | 1.15 Billion USD | -143.795% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -22935.127% |
| Veru Inc. | 50.59 Million USD | -5460.112% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -6075.642% |
| Cingulate Inc. | 3.49 Million USD | -80474.01% |
| Passage Bio, Inc. | 150.54 Million USD | -1768.67% |
| Context Therapeutics Inc. | 16.06 Million USD | -17413.767% |
| Exicure, Inc. | 11.58 Million USD | -24193.523% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -648.093% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -1640.383% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -16001.133% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -745.449% |
| Nuvalent, Inc. | 732.38 Million USD | -284.114% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -18724.78% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -3041.334% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -19723.762% |
| OmniAb, Inc. | 401.98 Million USD | -599.825% |
| Anew Medical, Inc. | 19.45 Million USD | -14359.276% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -10425.823% |
| Lipocine Inc. | 23 Million USD | -12130.691% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -1912.195% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -820.652% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -3251.38% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -2214.621% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -35352.93% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -218.856% |
| Ocugen, Inc. | 64.54 Million USD | -4258.359% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -2158.846% |
| Q32 Bio Inc. | 306.11 Million USD | -818.986% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -66753.375% |
| Alumis Inc. Common Stock | 89.61 Million USD | -3039.301% |
| Equillium, Inc. | 50.53 Million USD | -5467.366% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -3641.193% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -6715.968% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -165298.773% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -10661.601% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -4265.528% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -75379.064% |
| Dominari Holdings Inc. | 57.55 Million USD | -4787.574% |
| Edesa Biotech, Inc. | 8.89 Million USD | -31542.876% |
| vTv Therapeutics Inc. | 11.01 Million USD | -25432.674% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -200.196% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -246.688% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -913.16% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -6645.935% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -321.396% |
| Nkarta, Inc. | 378.88 Million USD | -642.492% |
| BioCardia, Inc. | 2.98 Million USD | -94081.118% |
| Iterum Therapeutics plc | 26.25 Million USD | -10613.241% |